EUCTR2011-005279-18-GB进行中（未招募）1 期
A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide. - MAJIC
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria for PV
- •Male or female patient = 18 years of age
- •A confirmed diagnosis of high risk* PV
- •*High Risk is defined as ANY ONE of the following:
- •- Age >60 years
- •- Previous documented thrombosis (including Transient Ischaemic Attack (TIA)), erythromelalgia or migraine (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before diagnosis and considered to be disease related
- •- Significant splenomegaly (i.e. > 5cm below costal margin on palpation) or symptomatic (splenic infarcts or requiring analgesia)
- •- Platelets > 1000 x 10^9/L
- •- Diabetes or hypertension requiring pharmacological therapy for > 6 months
- •Inclusion criteria for ET
- •Male or female patient = 18 years of age
- •A confirmed diagnosis of high risk* ET
- •*High risk is defined as ANY ONE of the following:
- •- Age > 60 years
- •- Platelet count > 1500 x 10^9/L
- •- Previous documented thrombosis (including Transient Ischaemic Attack (TIA)), erythromelalgia or migraine (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before diagnosis and considered to be disease related
- •- Previous haemorrhage related to ET
- •- Diabetes or hypertension requiring pharmacological therapy for > 6 months
- •ALL patients MUST ALSO be EITHER intolerant OR resistant to Hydroxycarbamide (HC) based on the following established criteria:
- •Any ONE of the following:
- •- Platelet count >600 x 10^9/L after 8 weeks of at least 2 g/day or MTD of HC (2.5 g/day in patients with a body weight>80 kg)
- •- Platelet count >400 x 10^9/L and WBC < 2.5 x 10^9/L at any dose of HC (for a period of at least 8 weeks)
- •- Platelet count >400 x 10^9/L and Hb < 11 g/dl at any dose of HC (for a period of at least 8 weeks)
- •- Platelet count persistently <100 x 109/L at any dose of HC (for a period of at least 8 weeks)
- •- Progressive splenomegaly or hepatomegaly i.e. enlargement by more than 5cm or appearance of new splenomegaly or hepatomegaly on HC treatment
- •- Not achieving the desired reduction of haematocrit or packed cell volume with the addition of HC in patients who do not tolerate frequent venesections after 8 weeks of at least 2 g/day of HC (2.5 g/day in patients with a body weight >80 kg)
- •- Not achieving the desired stable reduction of WBC when leukocytes are a target of therapy after 8 weeks of at least 2 g/day or MTD of HC (2.5 g/day in patients with a body weight>80 kg)
- •- Thrombosis or haemorrhage (including Transient Ischaemic Attack (TIA)) while on therapy
- •- Presence of leg ulcers or other unacceptable HC-related non-haematological toxicities, such as unacceptable mucocutaneous manifestations, gastrointestinal symptoms, pneumonitis or fever at any dose of HC. OR Cycling platelet counts on therapy
- •- Disease related symptoms not controlled by hydroxycarbamide
- •The patient can have met any one of the above criteria AT ANY POINT in their disease whilst on Hydroxycarbamide.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 145
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 145
排除标准
- •Pregnant and lactating patients (patients of childbearing potential must have a negative pregnancy test prior to study entry)
- •Patients and partners of childbearing potential not willing to use effective contraception
- •ECOG Performance Status Score = 3
- •Uncontrolled rapid or paroxysmal atrial fibrillation, uncontrolled or unstable angina, recent (6 months) myocardial infarction or acute coronary syndrome or any clinically significant cardiac disease > NYHA Class II
- •Patients who have transformed to myelofibrosis
- •Previous treatment with ruxolitinib
- •Previous (within the last 12 months) or current platelet count <100 x 10^9/L or neutrophil count < 1 x 10^9/L not due to therapy.
- •Inadequate liver function as defined by ALT/AST >1.5 x ULN
- •Inadequate renal function as defined by GFR < 15 mls/min
- •Unable to give informed consent
研究者
相似试验
已完成
不适用
Physical Counterpressure manoeuvre trialVasovagal syncopeSyncopeISRCTN45146526Academic Medical Center (AMC) (The Netherlands)200
尚未招募
不适用
Randomized clinical trial comparing treatment outcomes including adverse events of preoperative drainage for acute cholecystitis with endoscopic ultrasound and percutaneous transhepatic approachacute cholecystitisJPRN-UMIN000047820Osaka Medical and Pharmaceutical University80
尚未招募
2 期
To compare the effectiveness of needling with 5-fluorouracil 5% cream versus topical 88% phenol application in the treatment of vitiligoCTRI/2023/07/055803Vinayaka Missions Medical College
招募中
不适用
Randomised comparison study: eradication therapy for Helicobacter pylori with or without ecabet sodium after endoscopic submucosal dissection (ESD) of early gastric cancerH.pylori positive early gastric cancer patient who underwent an ESD.JPRN-UMIN000007735Department of Gastroenterology, Kitasato University School of Medicine330
尚未招募
不适用
Comparative Study of Therapeutic Efficacy and Safety of Glycolic Acid 6% and Azelaic Acid 20% in MelasmaCTRI/2021/06/034044ARULVASAN S S